Company

Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin.

In February 2012 Biofrontera launched the prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through various local representatives. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012.

US FDA approval of Ameluz® and activating PDT-lamp BF-RhodoLED® for the treatment of actinic keratoses was granted in May 2016.

As a cosmeceutical product Biofrontera markets Belixos® creme for the regenerative care of reddened and inflamed skin. It is Biofrontera’s intention to develop a line of cosmeceutical products for damaged skin under the Belixos brand.

The Biofrontera Group consists of the parent company Biofrontera AG and five wholly owned direct subsidiaries - Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, Biofrontera Neuroscience GmbH and Biofrontera Inc. Biofrontera Inc. has its registered office in Wakefield, MA, USA. All the other companies are based at Hemmelrather Weg 201 in 51377 Leverkusen, Germany.

The listed public limited company (AG in German) has a holding function in the group of companies and ensures the necessary financing for the Group. Biofrontera Bioscience GmbH undertakes the research and development tasks for the Group and is the holder of patents and the approval for Ameluz®. Based on a licence agreement with Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, which is also the holder of the approval for BF-RhodoLED®, is responsible for the manufacturing and also the further licensing and marketing of the Biofrontera Group’s approved products.

Biofrontera Development GmbH and Biofrontera Neuroscience GmbH were established as additional wholly owned subsidiaries of Biofrontera AG in December 2012. The purpose of both companies is to pursue the further development of pipeline products that are not part of Biofrontera's core business and therefore cannot be sufficiently financed within the framework of normal business development. The product BF-derm1, which is intended for the treatment of severe chronic urticaria, is the responsibility of Biofrontera Development GmbH, while the product BF-1, which is intended for the prophylactic treatment of migraines, is the responsibility of Biofrontera Neuroscience GmbH. By outsourcing the development projects, a structure has been created through which the financing of the further development of these two products can be separated from the normal Group financing.

Biofrontera Inc. was established in March 2015 and is used to conduct business in the USA.

In Spain Biofrontera markets its products via its own branch, Biofrontera Pharma GmbH, sucursal en España.

The Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the current CEO.
Since 2006 Biofrontera is listed in the regulatory market under the ISIN DE0006046113, the company currently employs about 100 people.